ADHD shared care protocol
Please view the documents below for information on The Chipping Surgery and Gloucestershire ICB shared care agreement policy following ADHD diagnosis.
Shared Care Agreement Policy
Adult incidence is 3-4%
ADHD is a heterogenous behavioural syndrome characterised by symptoms of hyperactivity, impulsivity, and inattention.
Methylphenidate, atomoxetine, lisdexamfetamine and dexamfetamine are licensed in children over 6 and adolescence. NICE recommends methylphenadineas first line in adults with ADHD.
NICE guidelines state that treatment should only be initiated by appropriately qualified health care providers with expertise in ADHD.
NICE recommends that continued prescribing and monitoring of drug therapy may be performed by GPs under shared care arrangements, ensuring clear lines of communication between primary and secondary care are maintained.
The Chipping Surgery is not taking on any new shared care arrangements with regard to ADHD medications at this time. As per GMC guidance, if a GP is not confident to undertake these roles, then he/she is under no obligation to do so.
Right to choose partners e.g., Psychiatry UK, ADHD 360, Clinical partners;
https://adhduk.co.uk/right-to-choose/
https://g-care.glos.nhs.uk/pathway/429/resource/5#chapter_2833